From Tissue Architecture To Genetic Signature: Artificial intelligence-based Analysis of Reticulin Framework and Clinical Variables Predicts Molecular Cluster in Paragangliomas.

Eleonora Duregon¹, Mirko Parasiliti-Caprino^2,3, Giulia Orlando⁴, Anna Paola Ferrero³, Martina Bollati², Rute Pedrosa⁵, Darshan Kumar⁵, Giuseppe Giraudo⁶, Barbara Pasini⁷, Ezio Ghigo^2,3, Emanuela Arvat^3,8, Marco Volante⁴, Mauro Maccario^2,3, Mauro Papotti⁴

¹Department of Oncology, University of Turin, Turin, Orbassano, Italy. eleonora.duregon@unito.it.

²Arterial Hypertension and Cardiovascular Endocrinology Laboratory, Division of Endocrinology, Diabetes and Metabolism, City of Health and Sciences University Hospital, Turin, Italy.

³Department of Medical Science, University of Turin, Turin, Italy.

⁴Department of Oncology, University of Turin, Turin, Orbassano, Italy.

⁵Aiforia Technologies Plc, Helsinki, Finland.

⁶Division of Surgery, Department of General and Specialized Surgery, City of Health and Sciences University Hospital, Turin, Italy.

⁷Division of Medical Genetics, City of Health and Sciences University Hospital, Turin, Italy.

⁸Division of Oncological Endocrinology, City of Health and Sciences University Hospital, Turin, Italy.

PubMed PMC DOI PDF

Abstract

Paragangliomas (PGLs), encompassing pheochromocytomas and extra-adrenal paragangliomas, are genetically heterogeneous non-epithelial neuroendocrine neoplasms that segregate into molecular clusters with distinct biological and clinical behavior. Architectural correlates of genotype have not been systematically investigated. This study aimed to assess the reticulin framework as a potential morpholog…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.